Positive data for CureVac and GSK’s second generation COVID-19 shot 16-Aug-2021 By Jane Byrne CureVac and GSK said their jointly advanced second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in a preclinical study.